Airborne Preventive Measures to Reduce New TB Infections in Household Contacts (TBMask)
Strengthening of Airborne Preventive Measures Inside Households of Pulmonary TB Cases as a Tool to Reduce New Infections in Close Contacts. A Pilot, Controlled, Pre-post Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Romina Seguel, RN
- Phone Number: +56223543508
- Email: rjseguel@uc.cl
Study Locations
-
-
-
Santiago, Chile
- Pontificia Universidad Catolica de Chile
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- all household contacts of a new case of pulmonary TB (smear, culture or PCR positive) newly diagnosed at each clinic.
Exclusion Criteria:
- household contacts found to have co-prevalent active TB at enrolment
- household contacts planning to leave the house at the time of enrolment
- household contacts of index cases having already initiated TB treatment for > 48h
- household contacts of index cases that are currently hospitalized
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Respiratory Bundle Group
The intervention consists of a bundle of measures for respiratory transmission prevention that will be provided during the first 2 weeks of TB treatment of index case.
|
|
|
No Intervention: Standard of care
Under current national guidelines, no systematic recommendation regarding respiratory protection is given for household contacts of TB cases.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participation rate
Time Frame: 2 weeks
|
To document the proportion of TB cases and household contacts who agree to participate as measured by enrollment.
|
2 weeks
|
|
Study compliance
Time Frame: 2 weeks
|
To document participants compliance with the respiratory bundle as measured by a previously validated adherence questionnaire.
|
2 weeks
|
|
Completion rate
Time Frame: 12 weeks
|
The number of participants assessable at end of follow-up.
|
12 weeks
|
|
Acceptability of the intervention
Time Frame: 12 weeks
|
Focus group evaluation (participants and TB nurses perspectives, qualitative outcome).
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
New tuberculosis infections
Time Frame: 12 weeks
|
The number of participants converting from a negative to a positive latent TB test at follow-up.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: María Elvira Balcells, MD; MSc, School of Medicine. Pontificia Universidad Católica de Chile.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1211225
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
NCT04493671CompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis Infection
-
NCT05526911CompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis Infection
-
NCT07268664Not yet recruitingTuberculosis | Drug-resistant Tuberculosis | Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis
-
NCT02454205CompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant Tuberculosis
-
NCT07611695Not yet recruitingPulmonary Tuberculosis | Tuberculosis (TB) | Tuberculosis Active
-
NCT05017324RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant Tuberculosis
-
NCT07419568Not yet recruitingPregnancy | Maternal Health | Tuberculosis (TB) | Tuberculosis Diagnosis | Tuberculosis Infection, Latent
-
NCT01613196CompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone Tuberculosis
-
NCT00691392CompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant Tuberculosis
-
NCT04062201CompletedTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TB
Clinical Trials on Respiratory bundle
-
NCT06642285RecruitingMechanical Ventilation Complication | Respiratory Distress Syndrome in Premature Infant
-
NCT04347395CompletedPneumonia | Dysphagia | Respiratory Infection
-
NCT05231200Recruiting
-
NCT05110716Completed
-
NCT06553534Active, not recruitingCardiopulmonary Resuscitation | In-hospital Cardiac Arrest
-
NCT01033188CompletedKnee Outcome, Subjective
-
NCT05838690RecruitingInfant | Intubation Complication
-
NCT04749836RecruitingBundle-Branch Block | AV Block | Atrial Fibrillation Rapid
-
NCT06001164Completed
-
NCT02834962UnknownRupture of Anterior Cruciate Ligament